Spero Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on Thursday, March 27, 2025
Spero Therapeutics (SPRO), a multi-asset clinical-stage biopharmaceutical company focused on rare diseases and multi-drug resistant bacterial infections, has scheduled its Fourth Quarter and Full Year 2024 financial results announcement for March 27, 2025.
The company will host a conference call and audio webcast at 4:30 p.m. ET to discuss results and provide business updates. Investors can access the call via domestic (1-844-825-9789) or international (1-412-317-5180) dial-in numbers using conference ID 10196669.
Spero Therapeutics (SPRO), una società biofarmaceutica clinica multi-asset focalizzata su malattie rare e infezioni batteriche multiresistenti, ha programmato l'annuncio dei risultati finanziari del Quarto Trimestre e dell'Anno Completo 2024 per il 27 marzo 2025.
L'azienda ospiterà una conferenza telefonica e un webcast audio alle 4:30 p.m. ET per discutere i risultati e fornire aggiornamenti aziendali. Gli investitori possono accedere alla chiamata tramite numeri di accesso nazionali (1-844-825-9789) o internazionali (1-412-317-5180) utilizzando l'ID conferenza 10196669.
Spero Therapeutics (SPRO), una empresa biofarmacéutica en etapa clínica con múltiples activos centrada en enfermedades raras e infecciones bacterianas multirresistentes, ha programado el anuncio de sus resultados financieros del Cuarto Trimestre y del Año Completo 2024 para el 27 de marzo de 2025.
La empresa llevará a cabo una conferencia telefónica y un webcast de audio a las 4:30 p.m. ET para discutir los resultados y proporcionar actualizaciones comerciales. Los inversores pueden acceder a la llamada a través de números de acceso nacionales (1-844-825-9789) o internacionales (1-412-317-5180) utilizando el ID de conferencia 10196669.
Spero Therapeutics (SPRO)는 희귀 질환 및 다제내성 세균 감염에 중점을 둔 다중 자산 임상 단계의 생명공학 회사로, 2024년 4분기 및 전체 연도 재무 결과 발표를 2025년 3월 27일로 예정하고 있습니다.
회사는 오후 4시 30분 ET에 결과를 논의하고 비즈니스 업데이트를 제공하기 위해 전화 회의 및 오디오 웹캐스트를 개최합니다. 투자자들은 국내 전화번호 (1-844-825-9789) 또는 국제 전화번호 (1-412-317-5180)를 통해 회의 ID 10196669를 사용하여 전화를 접속할 수 있습니다.
Spero Therapeutics (SPRO), une entreprise biopharmaceutique en phase clinique axée sur les maladies rares et les infections bactériennes multirésistantes, a prévu d'annoncer ses résultats financiers du quatrième trimestre et de l'année complète 2024 pour le 27 mars 2025.
L'entreprise organisera une conférence téléphonique et un webinaire audio à 16h30 ET pour discuter des résultats et fournir des mises à jour sur l'entreprise. Les investisseurs peuvent accéder à l'appel via des numéros d'accès nationaux (1-844-825-9789) ou internationaux (1-412-317-5180) en utilisant l'ID de conférence 10196669.
Spero Therapeutics (SPRO), ein biopharmazeutisches Unternehmen in der klinischen Phase mit mehreren Vermögenswerten, das sich auf seltene Krankheiten und multiresistente bakterielle Infektionen konzentriert, hat die Bekanntgabe der finanziellen Ergebnisse für das 4. Quartal und das Gesamtjahr 2024 für den 27. März 2025 geplant.
Das Unternehmen wird um 16:30 Uhr ET eine Telefonkonferenz und einen Audio-Webcast veranstalten, um die Ergebnisse zu besprechen und Geschäftsinformationen bereitzustellen. Investoren können über nationale (1-844-825-9789) oder internationale (1-412-317-5180) Telefonnummern mit der Konferenz-ID 10196669 auf den Anruf zugreifen.
- None.
- None.
CAMBRIDGE, Mass., March 18, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that it will report its financial results for the fourth quarter and full year ended December 31, 2024, and provide a business update, on March 27, 2025. Management will host a conference call and live audio webcast to discuss the results at 4:30 p.m. ET.
To access the call, please dial 1-844-825-9789 (domestic) or 1-412-317-5180 (international) and refer to conference ID 10196669, or click on this link and request a return call. The Call me™ passcode is 9270590. The audio webcast can be accessed live on this link or on the “Events and Presentations” page under the “Investor Relations” tab of the Spero Corporate Website at https://sperotherapeutics.com. The archived webcast will also be available on Spero’s website for 30 days following the call.
About Spero Therapeutics
Spero Therapeutics, headquartered in Cambridge, Massachusetts, is a multi-asset, clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections. For more information, visit www.sperotherapeutics.com
Investor Relations Contact:
Shai Biran, PhD
Spero Therapeutics
IR@Sperotherapeutics.com
Media Inquiries:
media@sperotherapeutics.com
FAQ
When will Spero Therapeutics (SPRO) release Q4 and Full Year 2024 earnings?
How can investors join SPRO's Q4 2024 earnings call?
What is the main focus of Spero Therapeutics (SPRO)?
How long will SPRO's Q4 2024 earnings webcast be available?
